GSK’s Arexvy Leads Over Pfizer’s Abrysvo in Year One of RSV Vaccine Market Battle

In the first year of the respiratory syncytial virus (RSV) vaccine battle, GlaxoSmithKline’s (GSK) Arexvy emerged as the winner over Pfizer’s Abrysvo.

GSK declared Arexvy to be a blockbuster in its first year on the market after higher-than-expected sales. GSK revealed in its 2023 annual and quarterly earnings report last week that sales of Arexvy totaled $1.5 billion or £1.2 billion in 2023, higher than its $1 billion estimation.